What are the causes and treatment options for a patient with hypertriglyceridemia?

Causes and Treatment of Hypertriglyceridemia

Primary Causes and Contributing Factors

Hypertriglyceridemia results from a combination of genetic predisposition and modifiable lifestyle factors, with uncontrolled diabetes, obesity, and excessive alcohol consumption being the most common drivers.

Lifestyle and Dietary Factors

• Excess body weight and visceral adiposity are primary drivers, associated with reduced fatty acid oxidation in muscle tissue 1
• Excessive alcohol consumption dramatically elevates triglycerides—even 1 ounce daily increases levels by 5-10%, with effects synergistically worsened when combined with high saturated fat meals 1
• High intake of simple carbohydrates and added sugars directly increases hepatic triglyceride production by approximately 10 mg/dL independent of body weight 1
• Physical inactivity is strongly associated with elevated triglyceride levels 1

Medical Conditions (Secondary Causes)

• Uncontrolled diabetes mellitus is often the primary driver of severe hypertriglyceridemia, as poor glycemic control dramatically increases triglyceride production 1
• Hypothyroidism contributes to disordered lipid metabolism 1
• Chronic kidney disease and nephrotic syndrome elevate triglyceride levels 1
• Chronic liver disease disrupts triglyceride metabolism 1

Medications That Raise Triglycerides

• Thiazide diuretics, beta-blockers, estrogen therapy (particularly oral contraceptives and postmenopausal hormone preparations), corticosteroids, antiretroviral medications, and antipsychotics 2, 1

---

Classification and Risk Stratification

Triglyceride levels must be classified by severity to determine treatment intensity and primary therapeutic goals:

• Normal: <150 mg/dL 3
• Mild: 150-199 mg/dL 3
• Moderate: 200-499 mg/dL 3
• Severe: 500-999 mg/dL 3
• Very severe: ≥1,000 mg/dL 3

Mild to moderate hypertriglyceridemia increases cardiovascular disease risk, while severe and very severe levels (≥500 mg/dL) dramatically increase the risk of acute pancreatitis, with a 14% incidence at severe levels 1

---

Treatment Algorithm by Severity

For Mild to Moderate Hypertriglyceridemia (150-499 mg/dL)

Lifestyle Modifications (First-Line for All Patients)

• Target 5-10% body weight reduction, which produces a 20% decrease in triglycerides—the single most effective lifestyle intervention 1, 3
• Restrict added sugars to <6% of total daily calories, as sugar intake directly increases hepatic triglyceride production 1
• Limit total dietary fat to 30-35% of total calories, prioritizing polyunsaturated and monounsaturated fats over saturated fats (<7% of calories) 1
• Consume ≥2 servings (8+ ounces) per week of fatty fish rich in omega-3 fatty acids (salmon, trout, sardines) 1
• Engage in ≥150 minutes/week of moderate-intensity aerobic activity (or 75 minutes/week vigorous activity), which reduces triglycerides by approximately 11% 1, 3
• Limit or completely avoid alcohol consumption—complete abstinence is mandatory for severe hypertriglyceridemia 1, 3

Pharmacologic Therapy

• For patients aged 40-75 years with 10-year ASCVD risk ≥7.5% or elevated LDL-C, initiate moderate-to-high intensity statin therapy as first-line, which provides 10-30% dose-dependent triglyceride reduction plus proven cardiovascular benefit 1
• If triglycerides remain >200 mg/dL after 3 months of optimized lifestyle modifications and statin therapy, add icosapent ethyl (prescription EPA) 2g twice daily for patients with established cardiovascular disease or diabetes with ≥2 additional cardiovascular risk factors 1, 3
• Icosapent ethyl demonstrated a 25% reduction in major adverse cardiovascular events in the REDUCE-IT trial (number needed to treat = 21) 1

For Severe to Very Severe Hypertriglyceridemia (≥500 mg/dL)

This represents a medical emergency requiring immediate intervention to prevent acute pancreatitis.

Immediate Pharmacologic Intervention

• Initiate fenofibrate 54-160 mg daily immediately as first-line therapy, regardless of LDL-C levels or cardiovascular risk, to prevent acute pancreatitis 1, 3, 4
• Fenofibrate provides 30-50% triglyceride reduction 1, 4
• Do NOT start with statin monotherapy when triglycerides are ≥500 mg/dL—statins provide only 10-30% triglyceride reduction and are insufficient for preventing pancreatitis at this level 2

Critical Dietary Interventions

• For triglycerides 500-999 mg/dL: restrict total dietary fat to 20-25% of total daily calories 1
• For triglycerides ≥1,000 mg/dL: restrict total dietary fat to 10-15% of daily calories until levels fall below 1,000 mg/dL 2, 1
• Eliminate all added sugars completely 1
• Complete alcohol abstinence is mandatory—alcohol can precipitate hypertriglyceridemic pancreatitis at these levels 1

Urgent Assessment for Secondary Causes

• Check hemoglobin A1c and fasting glucose immediately—uncontrolled diabetes is often the primary driver, and optimizing glucose control can reduce triglycerides by 20-50% independent of lipid medications 2, 1
• Measure TSH to rule out hypothyroidism, which must be treated before expecting full response to lipid-lowering therapy 2
• Review all medications for agents that raise triglycerides and discontinue or substitute if possible 2

Sequential Treatment Approach

• Once triglycerides fall below 500 mg/dL with fenofibrate and lifestyle optimization, reassess LDL-C and consider adding statin therapy if LDL-C is elevated or cardiovascular risk is high 2, 1
• If triglycerides remain >200 mg/dL after 3 months of fenofibrate plus optimized lifestyle, add prescription omega-3 fatty acids (icosapent ethyl 2-4g daily) as adjunctive therapy 1, 3

---

Special Considerations and Safety

Combination Therapy Safety

• When combining fenofibrate with statins, use lower statin doses to minimize myopathy risk, particularly in patients >65 years or with renal disease 1, 3
• Use fenofibrate, NOT gemfibrozil, when combining with statins—fenofibrate has a significantly better safety profile with lower myopathy risk 1
• Monitor creatine kinase levels and muscle symptoms when using combination therapy 3

Renal Dosing Adjustments

• For patients with eGFR 30-59 mL/min/1.73 m²: start fenofibrate at 54 mg daily and do not exceed this dose 4
• Fenofibrate is contraindicated for patients with eGFR <30 mL/min/1.73 m² 4
• Monitor renal function within 3 months after fenofibrate initiation and every 6 months thereafter 4

---

Monitoring and Follow-Up

• Reassess fasting lipid panel in 6-12 weeks after implementing lifestyle modifications 1, 3
• Reassess lipids 4-8 weeks after initiating or adjusting pharmacotherapy 1, 3
• Monitor liver function tests and creatine kinase if fibrates are added, particularly at baseline and 3 months after initiation 1, 3

---

Treatment Goals

• Primary goal for severe hypertriglyceridemia: rapid reduction to <500 mg/dL to eliminate pancreatitis risk 1
• Secondary goal: further reduction to <200 mg/dL (ideally <150 mg/dL) to reduce cardiovascular risk 1
• Tertiary goal: non-HDL-C <130 mg/dL once triglycerides are controlled 1

---

Common Pitfalls to Avoid

• Do NOT delay fibrate therapy while attempting lifestyle modifications alone in patients with triglycerides ≥500 mg/dL—pharmacologic therapy is mandatory 2
• Do NOT use over-the-counter fish oil supplements expecting cardiovascular benefit—only prescription omega-3 formulations (icosapent ethyl) have proven cardiovascular outcomes 5
• Do NOT ignore secondary causes, particularly uncontrolled diabetes and hypothyroidism—treating these can be more effective than additional lipid medications 2, 1
• Do NOT discontinue statins in favor of fibrate monotherapy in patients with cardiovascular risk or established disease—statins provide proven mortality benefit through LDL-C reduction 2